Mereo BioPharma (MREO) Announces Updated Operating Plan to Maximize Shareholder Value
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/3/2026
- Wall St futures gain on Mideast deal hopes; healthcare in focus
- Fed's Williams says rate hikes possible if inflation persists
- Citi says buy these 3 chip stocks on pullback
- Microsoft joins, Broadcom exits Goldman's top-stocks list
- Deutsche Bank raises S&P 500 earnings estimates on the back of the solid Q2 beats
- Morgan Stanley Downgrades Circle Internet Group (CRCL) to Underweight
- Myanmar's detained former leader Aung San Suu Kyi meets Red Cross official
- Bernstein raises server shipment forecast as AI infrastructure spending grows
- Supernus and Indivior agree to all-stock merger of equals
- Curium to acquire Lantheus in deal valued at up to $8 billion
- After-Hours Stock Movers: AAPL, AMZN, COIN, RBLX, RDDT, AXTI, FND, WU, GDDY
- After-Hours Stock Movers: META, MSFT, CMG, SBUX, CVNA, LRCX, FTNT, QCOM, TDOC
- After-Hours Stock Movers: F, BE, STX, WDC, KLAC, SWKS, NXPI, CSGP, ENPH
- After-Hours Stock Movers: FFIV, CDNS, APLD, RMBS, ESI, SANM
- After-Hours Stock Movers: INTC, AMD, ARM, MXL, EW, DECK
Mereo BioPharma Announces Updated Operating Plan to Maximize Shareholder Value
October 18, 2022 7:00 AM EDTTargets 40% Reduction in Headcount and Significant Expense Reductions as Company Continues to Guide Lead Programs Through Upcoming Value Creating Milestones
Reiterates Commitment to Disciplined Capital Allocation and Management of Mereos Promising Pipeline
Provides Encouraging Development Updates on Lead Programs; Follows Alvelestats Fast Track Designation by the U.S. Food & Drug Administration
LONDON, Oct. 18, 2022 (GLOBE NEWSWIRE) -- Mereo BioPharma Group plc (NASDAQ: MREO), (Mereo or the Company), a clinical-stage biopharmaceutical company focused on rare diseases and oncology, today provided an... More
